Featured Research

from universities, journals, and other organizations

Routine screening for postnatal depression not cost effective, UK study finds

Date:
December 22, 2009
Source:
BMJ-British Medical Journal
Summary:
Routine screening for postnatal depression in primary care do not appear to represent value for money for the UK's National Health Service, concludes a new study.

Routine screening for postnatal depression in primary care -- as recommended in recent guidance from the National Institute for Health and Clinical Excellence (NICE) -- do not appear to represent value for money for the National Health Service, concludes a study published online in the British Medical Journal.

The results suggest that both the NICE guidance and widespread current practice should be reviewed.

More than one in 10 women suffer from postnatal depression six weeks after giving birth, yet fewer than half of cases are detected in routine clinical practice. Formal identification methods, such as postnatal or general depression questionnaires, have been advocated but have attracted substantial controversy.

Furthermore, guidelines issued by NICE in 2007 recommend the use of specific questions to identify possible postnatal depression, but the cost effectiveness of this strategy is uncertain.

So researchers at the University of York used a computer model to evaluate the cost effectiveness of formal methods to identify postnatal depression in primary care.

Routine use of either postnatal or general depression questionnaires did not appear to be cost effective compared with routine care only, largely due to the cost of managing those wrongly diagnosed as depressed, say the authors.

For example, the Edinburgh postnatal depression scale had an incremental cost effectiveness ratio of 41,103 per quality adjusted life year or QALY (a combined measure of quantity and quality of life) compared with routine care only.

The ratio for all other strategies ranged from 49,928 to 272,463 per QALY compared with routine care only, well above the conventional NHS cost effectiveness threshold of 20-30,000 per QALY.

In contrast, the strategy of administering only routine care was most likely to be cost effective.

These findings suggest that both the recent NICE guidance and widespread current practice do not result in value for money for the NHS, and do not satisfy the National Screening Committee's criteria for the adoption of a screening strategy as part of national health policy, conclude the authors

They call for further research to quantify the cost of incorrect diagnosis and the wider impact of postnatal depression treatment strategies on the quality of life of the mother and her family.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Routine screening for postnatal depression not cost effective, UK study finds." ScienceDaily. ScienceDaily, 22 December 2009. <www.sciencedaily.com/releases/2009/12/091222203013.htm>.
BMJ-British Medical Journal. (2009, December 22). Routine screening for postnatal depression not cost effective, UK study finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/12/091222203013.htm
BMJ-British Medical Journal. "Routine screening for postnatal depression not cost effective, UK study finds." ScienceDaily. www.sciencedaily.com/releases/2009/12/091222203013.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins